Rosa B. Barkardottir

Reykjavik, Iceland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 78 publications

Targeted therapy in the treatment of lung cancer in Iceland 2010-2023.

Targeted therapy in the treatment of lung cancer in Iceland 2010-2023.

Journal: Acta oncologica (Stockholm, Sweden)
Published: December 01, 2025

Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.

Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.

Journal: Nature communications
Published: September 09, 2025

Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk.

Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk.

Journal: medRxiv : the preprint server for health sciences
Published: March 18, 2024

Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer.

Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer.

Journal: NPJ genomic medicine
Published: March 14, 2024

A Breast Cancer Candidate Locus at 6q Narrowed to 6q15-q21.

A Breast Cancer Candidate Locus at 6q Narrowed to 6q15-q21.

Journal: Genes
Published: January 09, 2024

High Atlastin 2-2 (ATL2-2) Expression Associates with Worse Prognosis in Estrogen-Receptor-Positive Breast Cancer.

High Atlastin 2-2 (ATL2-2) Expression Associates with Worse Prognosis in Estrogen-Receptor-Positive Breast Cancer.

Journal: Genes
Published: June 20, 2023

Estrogen receptor-positive breast cancer and adverse outcome in BRCA2 mutation carriers and young non-carrier patients.

Estrogen receptor-positive breast cancer and adverse outcome in BRCA2 mutation carriers and young non-carrier patients.

Journal: NPJ breast cancer
Published: May 26, 2023

Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

Journal: European journal of human genetics : EJHG
Published: March 22, 2022

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.

Journal: Communications biology
Published: November 15, 2021

Hsa-miR-21-3p associates with breast cancer patient survival and targets genes in tumor suppressive pathways.

Hsa-miR-21-3p associates with breast cancer patient survival and targets genes in tumor suppressive pathways.

Journal: PloS one
Published: July 23, 2021

Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.

Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.

Journal: Journal of the National Cancer Institute
Published: February 16, 2021

Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

Journal: European journal of human genetics : EJHG
Published: December 07, 2020
Showing 1-12 of 78

Last Updated: 09/26/2026